Case Study: Nephron pharmaceuticals compounding facility integrates VHP biodecontamination

The growing manufacturer of generic respiratory medications and a contract manufacturer of blow-fill-seal products has chosen STERIS to integrate a VHP biodecontamination system

To download the full case study, follow this link

Nephron is a rapidly growing manufacturer of generic respiratory medications and a contract manufacturer of blow-fill-seal products. Also, as a 503B compounder, Nephron has made significant investments in the production of high-volume pharmaceutical preparations for interstate distribution. Adapting their production output to the constantly changing needs of the market requires frequent product changeover activities. Pharmaceutical compounding is a time- and labour-intensive venture. Production processes are strictly regulated for quality and safety. Workers require a high level of training and to meet demand, facilities remain in continuous operation.

To meet the aseptic standards associated with this type of work, Nephron spends a considerable amount of time and resources cleaning and disinfecting large production spaces.

In 2018, they embarked on a joint project with STERIS to investigate the use of an integrated vaporized hydrogen peroxide (VHP) biodecontamination system to reduce the time associated with manual disinfection. This case study will provide insight into Nephron's experience adopting an integrated VHP approach, the challenges encountered, and results achieved.



To read more download the full case study, follow this link

Featured Companies

Steris Life Sciences (more information, website)